Laubli H - Search Results

1

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Joerger M, Calvo E, Laubli H, Lopez J, Alonso G, Corral de la Fuente E, Hess D, König D, Sanchez Perez V, Bucher C, Jethwa S, Garralda E. Joerger M, et al. Among authors: laubli h. J Immunother Cancer. 2023 Nov 21;11(11):e007784. doi: 10.1136/jitc-2023-007784. J Immunother Cancer. 2023. PMID: 38243906 Free PMC article. Clinical Trial.

2

Sialic acid-binding immunoglobulin-like lectins (Siglecs) detect self-associated molecular patterns to regulate immune responses.

Läubli H, Varki A. Läubli H, et al. Cell Mol Life Sci. 2020 Feb;77(4):593-605. doi: 10.1007/s00018-019-03288-x. Epub 2019 Sep 4. Cell Mol Life Sci. 2020. PMID: 31485715 Free PMC article. Review.

3

Involvement of a non-human sialic Acid in human cancer.

Samraj AN, Läubli H, Varki N, Varki A. Samraj AN, et al. Among authors: laubli h. Front Oncol. 2014 Feb 19;4:33. doi: 10.3389/fonc.2014.00033. eCollection 2014. Front Oncol. 2014. PMID: 24600589 Free PMC article. Review.

4

Selectin-mediated activation of endothelial cells induces expression of CCL5 and promotes metastasis through recruitment of monocytes.

Läubli H, Spanaus KS, Borsig L. Läubli H, et al. Blood. 2009 Nov 12;114(20):4583-91. doi: 10.1182/blood-2008-10-186585. Epub 2009 Sep 24. Blood. 2009. PMID: 19779041 Free article.

5

Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

Pearce OM, Läubli H, Bui J, Varki A. Pearce OM, et al. Among authors: laubli h. Oncoimmunology. 2014 Jun 25;3:e29312. doi: 10.4161/onci.29312. eCollection 2014. Oncoimmunology. 2014. PMID: 25083340 Free PMC article.

6

Selectins as mediators of lung metastasis.

Läubli H, Borsig L. Läubli H, et al. Cancer Microenviron. 2010 Feb 27;3(1):97-105. doi: 10.1007/s12307-010-0043-6. Cancer Microenviron. 2010. PMID: 21209777 Free PMC article.

7

Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.

Läubli H, Pearce OM, Schwarz F, Siddiqui SS, Deng L, Stanczak MA, Deng L, Verhagen A, Secrest P, Lusk C, Schwartz AG, Varki NM, Bui JD, Varki A. Läubli H, et al. Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):14211-6. doi: 10.1073/pnas.1409580111. Epub 2014 Sep 15. Proc Natl Acad Sci U S A. 2014. PMID: 25225409 Free PMC article.

8

Lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a tumor-associated immunomodulatory ligand for CD33-related Siglecs.

Läubli H, Alisson-Silva F, Stanczak MA, Siddiqui SS, Deng L, Verhagen A, Varki N, Varki A. Läubli H, et al. J Biol Chem. 2014 Nov 28;289(48):33481-91. doi: 10.1074/jbc.M114.593129. Epub 2014 Oct 15. J Biol Chem. 2014. PMID: 25320078 Free PMC article.

9

Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies.

Pearce OM, Läubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. Pearce OM, et al. Among authors: laubli h. Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):5998-6003. doi: 10.1073/pnas.1209067111. Epub 2014 Apr 7. Proc Natl Acad Sci U S A. 2014. PMID: 24711415 Free PMC article.

10

High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity.

Vazquez-Lombardi R, Jung JS, Schlatter FS, Mei A, Mantuano NR, Bieberich F, Hong KL, Kucharczyk J, Kapetanovic E, Aznauryan E, Weber CR, Zippelius A, Läubli H, Reddy ST. Vazquez-Lombardi R, et al. Among authors: laubli h. Immunity. 2022 Oct 11;55(10):1953-1966.e10. doi: 10.1016/j.immuni.2022.09.004. Epub 2022 Sep 28. Immunity. 2022. PMID: 36174557 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page